Last Updated: 10/19
Share or print this information to talk to your doctor about this trial.
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy.
18 and older
Novartis Investigative Site
Newcastle Upon Tyne, NE7 7DN
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
1-888-669-6682 | email@example.com | +41613241111
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
Continued use of this site indicates you have accepted this policy.